CHINA NATIONAL MEDICINES CORPORATION LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 34.38 CNY | -2.63% |
|
+1.12% | +20.13% |
| Sales 2024 * | 53.36B 7.36B | Sales 2025 * | 59.07B 8.15B | Capitalization | 25.94B 3.58B |
|---|---|---|---|---|---|
| Net income 2024 * | 2.4B 331M | Net income 2025 * | 2.62B 361M | EV / Sales 2024 * | 0.49 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 0.44 x |
| P/E ratio 2024 * |
10.8
x | P/E ratio 2025 * |
9.91
x | Employees | - |
| Yield 2024 * |
2.76% | Yield 2025 * |
2.97% | Free-Float | 42.95% |
More Fundamentals
* Assessed data
More news
| 1 day | -2.63% | ||
| 1 week | +1.12% | ||
| Current month | +1.12% | ||
| 1 month | -5.16% | ||
| 3 months | +13.05% | ||
| 6 months | +22.04% | ||
| Current year | +20.13% |
1 week
34.07
35.99
1 month
33.9237.80
Current year
27.1837.80
1 year
26.5839.29
3 years
24.3644.80
5 years
21.4262.95
10 years
19.8162.95
| Managers | Title | Age | Since |
|---|---|---|---|
Guo Tao Tian
CEO | Chief Executive Officer | 54 | 21-07-31 |
Fei Chen
DFI | Director of Finance/CFO | 49 | 23-10-13 |
Xiu Chang Jiang
CHM | Chairman | 60 | 99-11-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Xiao Juan Li
BRD | Director/Board Member | 48 | 22-04-06 |
Xing Xi Yu
BRD | Director/Board Member | 66 | 22-04-06 |
Yong Liu
BRD | Director/Board Member | 55 | 10-03-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.33% | 1 M€ | -18.21% | - | |
| 0.00% | 32 M€ | +4.30% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-07 | 34.38 | -2.63% | 5,733,400 |
| 24-06-06 | 35.31 | +1.47% | 6,788,400 |
| 24-06-05 | 34.8 | -0.77% | 4,422,200 |
| 24-06-04 | 35.07 | +2.60% | 5,712,418 |
| 24-06-03 | 34.18 | +0.53% | 3,785,044 |
End-of-day quote Shanghai S.E., June 06, 2024
More quotes
China National Medicines Corporation Ltd. is a China-based company principally engaged in the distribution of pharmaceutical products. The Company's primary products include proprietary Chinese medicines, chemical medicine preparations, chemical raw materials, antibiotics, biochemical drugs, biological products, narcotic drugs, psychotropic drugs, vaccines and health foods, among others. The Company is also involved in the production of pharmaceuticals and the provision of warehousing services through its subsidiaries.
Sector
Pharmaceuticals
Calendar
2024-08-21
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
34.38
CNY
Average target price
44.3
CNY
Spread / Average Target
+28.85%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +20.13% | 3.58B | |
| +26.77% | 76.29B | |
| -2.27% | 23.99B | |
| +10.27% | 9.01B | |
| +12.25% | 8.67B | |
| -24.34% | 7.58B | |
| +13.37% | 5.18B | |
| +2.34% | 4.16B | |
| -4.96% | 3.98B | |
| -1.36% | 3.63B |
- Stock Market
- Equities
- 600511 Stock
